Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Revenue (2016 - 2025)

Protalix BioTherapeutics has reported Revenue over the past 16 years, most recently at $9.1 million for Q4 2025.

  • Quarterly results put Revenue at $9.1 million for Q4 2025, down 49.93% from a year ago — trailing twelve months through Dec 2025 was $52.7 million (down 1.23% YoY), and the annual figure for FY2025 was $52.7 million, down 1.23%.
  • Revenue for Q4 2025 was $9.1 million at Protalix BioTherapeutics, down from $17.9 million in the prior quarter.
  • Over the last five years, Revenue for PLX hit a ceiling of $35.1 million in Q2 2023 and a floor of $3.7 million in Q1 2024.
  • Median Revenue over the past 5 years was $10.9 million (2021), compared with a mean of $12.9 million.
  • Biggest five-year swings in Revenue: skyrocketed 300.72% in 2023 and later crashed 61.59% in 2024.
  • Protalix BioTherapeutics' Revenue stood at $8.5 million in 2021, then increased by 0.8% to $8.6 million in 2022, then increased by 21.69% to $10.5 million in 2023, then surged by 73.74% to $18.2 million in 2024, then crashed by 49.93% to $9.1 million in 2025.
  • The last three reported values for Revenue were $9.1 million (Q4 2025), $17.9 million (Q3 2025), and $15.7 million (Q2 2025) per Business Quant data.